Apotex asks Supreme Court to overturn Teva ‘Bendeka’ ruling
21-12-2021
Eli Lilly secures Alimta patent win over Apotex
02-01-2020
Eli Lilly bids to stop generics cutting Alimta exclusivity
23-08-2013
Jonathan Weiss / Shutterstock.com
The US Court of Appeals for the Federal Circuit yesterday, December 21, upheld Eli Lilly’s success in barring the sale of a copycat version of cancer treatment Alimta (pemetrexed disodium).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Eli, Lilly, Apotex, Alimta, patent, pemetrexed, disodium, Federal. Circuit, appeal
